Denosumab Management for Osteoporosis and Cancer Treatment-Induced Bone Loss

Introduction to Denosumab Therapy

The American College of Physicians recommends administering 60 mg of denosumab subcutaneously every 6 months for osteoporosis, with mandatory calcium and vitamin D supplementation, pre-treatment dental evaluation, and transitioning to bisphosphonate therapy if denosumab is discontinued to prevent rebound vertebral fractures 1

The National Osteoporosis Foundation suggests administering 60 mg of denosumab subcutaneously every 6 months for osteoporosis in postmenopausal women, men with osteoporosis, and patients with cancer treatment-induced bone loss 1, 2
For bone metastases from cancer, the National Comprehensive Cancer Network recommends a different dose of 120 mg monthly 3, 4

The American Society of Clinical Oncology recommends continuing treatment for 3 to 5 years for cancer treatment-induced bone loss (aromatase inhibitors or androgen deprivation therapy) 5, 2
For multiple myeloma or bone metastases, the National Comprehensive Cancer Network suggests continuing up to 2 years with extension based on clinical judgment 4, 2

The American Dental Association recommends performing dental examination before initiating denosumab to minimize osteonecrosis of the jaw (ONJ) risk 1
The National Osteoporosis Foundation suggests that all patients must receive calcium 1,000 mg daily and vitamin D 400-600 IU daily throughout treatment 1

The American College of Rheumatology warns that stopping denosumab abruptly causes rebound bone loss and risk of multiple vertebral fractures, and recommends immediately transitioning to bisphosphonate therapy if denosumab is discontinued 2, 6
The National Comprehensive Cancer Network reports that denosumab showed similar time to skeletal-related events and overall survival compared to zoledronic acid, with lower renal toxicity but higher hypocalcemia rates 4

The Kidney Disease: Improving Global Outcomes (KDIGO) organization advises that patients with advanced chronic kidney disease are at markedly increased risk of severe hypocalcemia, and treatment should be supervised by a provider experienced in CKD-MBD management 7

The American Society of Clinical Oncology reports that denosumab increases BMD more than oral bisphosphonates at 12 months (total hip, lumbar spine, femoral neck) 3
The National Comprehensive Cancer Network suggests considering denosumab as an alternative when bisphosphonates are unsuitable due to compliance issues, intolerance, administration difficulty, or renal impairment 5, 8

The American College of Physicians recommends never stopping denosumab without transitioning to bisphosphonate therapy to prevent multiple vertebral fractures 2, 6